Abstract
IntroductionImatinib is a tyrosine kinase inhibitor (TKI) widely used in the treatment of chronic myeloid leukaemia and other malignancies in which tyrosine kinases are over expressed. The first case of...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
